Related Experiment Video

Updated: Apr 12, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K

miR-520h is crucial for DAPK2 regulation and breast cancer progression

C-M Su1,2, M-Y Wang3, C-C Hong4

  • 1Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.

Oncogene
|May 19, 2015
PubMed

Insights

MicroRNA 520h (miR-520h) promotes breast cancer drug resistance by suppressing DAPK2, leading to paclitaxel resistance. Higher miR-520h levels correlate with poor prognosis and metastasis in patients.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • MicroRNAs (miRNAs) regulate gene expression and are implicated in cancer.
  • Functional roles of specific miRNAs in breast cancer chemoresistance remain underexplored.
  • Identifying key miRNAs and targets is crucial for improving breast cancer treatment.

Purpose of the Study:

  • To identify and functionally characterize microRNAs involved in breast cancer drug resistance.
  • To elucidate the mechanism by which miR-520h confers chemoresistance.
  • To evaluate miR-520h as a prognostic marker in breast cancer.

Main Methods:

  • Bioinformatics prediction of miRNA targets.
  • Functional validation using cell-based assays (e.g., apoptosis, drug resistance).
  • Expression analysis in patient samples.

Main Results:

  • MicroRNA 520h (miR-520h) was identified as a key mediator of drug resistance in breast cancer cells.
  • miR-520h confers resistance to paclitaxel by inhibiting apoptosis.
  • miR-520h directly targets and suppresses Death-associated protein kinase 2 (DAPK2) expression.
  • Restoring DAPK2 expression abrogated miR-520h-mediated drug resistance.
  • Higher miR-520h levels are associated with poor prognosis and lymph node metastasis in breast cancer patients.

Conclusions:

  • miR-520h plays a significant role in promoting chemoresistance in human breast cancer.
  • The miR-520h/DAPK2 axis is a critical pathway in breast cancer drug resistance.
  • miR-520h serves as an independent prognostic factor and a potential therapeutic target for breast cancer.

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K
Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

24.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K